The emerging role of MET/HGF inhibitors in oncology

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The MET receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are crucial for cell growth, proliferation, survival, and motility.
• Aberrant activation of the MET/HGF pathway is implicated in various cancers, promoting tumor proliferation and metastasis.
• MET/HGF signaling contributes to oncogenesis through growth factor receptor and other oncogenic pathways.

Purpose of the Study:

• To review the role of MET/HGF signaling in cancer.
• To highlight the therapeutic potential of MET/HGF inhibition in targeted anticancer strategies.
• To discuss the clinical development and emerging biomarkers for MET/HGF targeted therapies.

Main Methods:

• Preclinical studies demonstrating the abrogation of neoplastic and metastatic phenotypes by MET inhibition.
• Review of ongoing clinical trials involving MET inhibitors such as tivantinib, cabozantinib, and others.
• Analysis of emerging evidence for biomarkers to identify patient subpopulations for targeted treatment.

Main Results:

• MET inhibition effectively abrogated neoplastic and metastatic phenotypes in preclinical models of non-small cell lung cancer, hepatocellular carcinoma, and gastric cancer.
• Clinical trials with several MET inhibitors have yielded encouraging results, establishing MET's key role in diverse tumor types.
• Evidence suggests the potential for identifying biomarkers to guide patient selection for MET and HGF inhibitor therapies.

Conclusions:

• Targeted inhibition of the MET/HGF pathway represents a promising therapeutic strategy for various cancers.
• MET inhibitors have demonstrated efficacy in preclinical models and are progressing through clinical development.
• Further research into biomarkers will be essential for optimizing patient selection and treatment outcomes for MET/HGF targeted therapies.